News & Analysis as of

Machine Learning Regulatory Reform Artificial Intelligence

Mintz - Antitrust Viewpoints

US Copyright Office Releases Third Report on AI Copyrightability, and House Committee Advances AI Legislation — AI: The Washington...

On May 9, the United States Copyright Office (Office) issued a pre-publication version of its third Report on Copyright and Artificial Intelligence (Report), which focuses on the question of the use of copyrighted materials...more

Epstein Becker & Green

Copyright Infringement Liability for Generative AI Training Following the Copyright Office’s AI Report and Administrative Shakeup

Epstein Becker & Green on

When multiple forces act on an object, its direction of motion is determined by the net force, which is the vector sum of all individual forces. When this happens within our federal government, we call it “interesting times.”...more

DLA Piper

Becoming the World’s Leading AI Continent: The Commission’s “AI Continent Action Plan”

DLA Piper on

The European Commission has shortly published its “AI Continent Action Plan” and, doing so, set itself no less a task than winning the global race for AI leadership and making Europe the leading AI continent. This shall be...more

McDermott Will & Emery

Quit Monkeying Around: FDA Offers Faster Approval Times in Bid to Phase Out Animal Testing

On April 10, 2025, the US Food and Drug Administration (FDA) announced its intent to phase out the use of animal testing in the development of certain drugs and biologics. To help bring this “paradigm shift in drug...more

Hogan Lovells

FDA animal testing phaseout urges AI-based trial alternatives, organoids, other “NAMs”

Hogan Lovells on

The U.S. Food and Drug Administration (FDA) recently announced it plans to phase out animal testing in the development of monoclonal antibody therapies and other drugs and biological products “with more effective,...more

Troutman Pepper Locke

Predicting Where State AGs Will Direct Their Attention in 2025

Troutman Pepper Locke on

In the first installment of this two-part article, state attorneys general across the U.S. took bold action in 2024 to address what they perceived as unlawful activities by corporations in several areas, including privacy and...more

Dacheng

China Monthly Data Protection Update: April 2025

Dacheng on

This monthly report outlines key developments in China’s data protection sector for April....more

Troutman Pepper Locke

Trump Administration’s First Export Control Action – Reading the Tea Leaves

Troutman Pepper Locke on

On March 25, the U.S. Department of Commerce’s Bureau of Industry and Security (BIS) announced a significant expansion of its Entity List restrictions, adding 80 entities from China, the United Arab Emirates, South Africa,...more

Brownstein Hyatt Farber Schreck

California’s AI Policy Direction: Key Insights and Business Implications

On March 18, 2025, the Joint California Policy Working Group on AI Frontier Models released a draft report outlining principles for AI regulation in California. This effort follows Gov. Gavin Newsom’s 2024 veto of SB 1047...more

Dacheng

DeepSeek and China’s AI Regulatory Landscape: Rules, Practice and Future Prospects

Dacheng on

During the 2025 Chinese New Year, DeepSeek, a Chinese artificial intelligence (“AI”) model, garnered intense global attention and sparked heated discussions. It surpassed ChatGPT, which had been in the spotlight previously,...more

Frost Brown Todd

Proposed HIPAA Security Rule Requires AI Governance

Frost Brown Todd on

In terms of healthcare data breaches, 2024 was the worst year ever, with the records of at least 53% of the U.S. population involved and two of the biggest healthcare data breaches of 2024 ranking in the top 10 of all time. ...more

DLA Piper

FDA in focus: 2024 in review and 2025 outlook

DLA Piper on

In 2024, the Food and Drug Administration (FDA) significantly invested in reorganizing its internal infrastructure and enhancing operations. These efforts aimed to address the complexities of a global supply chain, rapid...more

Seyfarth Shaw LLP

Commercial Litigation Outlook - 2025

Seyfarth Shaw LLP on

Last year’s Commercial Litigation Outlook was dominated by the promise and peril that AI poses to myriad industries. No doubt, the evolution of AI in the last year has been significant, and it is still a material...more

Gardner Law

FDA Layoffs, RFK Jr. at HHS, and What This Means for FDA-Regulated Companies

Gardner Law on

In recent weeks, the FDA has faced significant cuts, including the layoffs of probationary employees. These employees, many of whom had been hired to fill roles left by retirees or to bolster the agency’s staffing during the...more

Baker Donelson

The Colorado AI Act Shuffle: One Step Forward, Two Steps Back

Baker Donelson on

Colorado waded into the deep end of AI regulation last year with the Colorado AI Act (Senate Bill 24-205), a sweeping law designed to rein in the risks of artificial intelligence (AI) and automated decision systems (ADS)....more

Akin Gump Strauss Hauer & Feld LLP

2025 Perspectives in Private Equity: Health Care & Life Sciences

Private equity investors in health care and life sciences must navigate a complex and shifting landscape influenced by regulatory and policy changes and technological advancements. As private equity investments in the health...more

DLA Piper

EU AI Act’s Ban on Prohibited Practices Takes Effect

DLA Piper on

The first compliance deadline set out in the European Union (EU)’s Regulation (EU) 2024/1689, or the EU AI Act, took effect on February 2, 2025. ...more

Baker Botts L.L.P.

Intellectual Property Report February 2025

Baker Botts L.L.P. on

It is well established that “a petitioner in an inter partes review … is not permitted to assert a ground of unpatentability under 35 U.S.C. § 112.” Dexcowin Golabl, Inc. v. Aribex, Inc., IPR2016-00436, Paper 12 (PTAB July 7,...more

Polsinelli

USPTO Announces New Artificial Intelligence Strategy

Polsinelli on

Synopsis: On January 14, 2025, the USPTO unveiled a new Artificial Intelligence (AI) Strategy, which outlines responsible implementation of AI within the agency and more generally across the intellectual property (IP)...more

Alston & Bird

Trump Administration Rescinds Biden Executive Order on Artificial Intelligence

Alston & Bird on

What Happened? Last week, President Trump signed an Executive Order that rescinded the Biden Administration’s October 2023 Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence....more

DLA Piper

White House AI Executive Order Sets its Sights on Free-Market Innovation - Increased state-level regulation potentially on the...

DLA Piper on

On January 23, 2025, President Donald Trump signed the Executive Order (EO) Removing Barriers to American Leadership in Artificial Intelligence. The artificial intelligence (AI)- focused EO is anticipated by the White House...more

Quarles & Brady LLP

Day Three of Trump’s Presidency Provides Additional Clarity on the Administration’s Stance on AI

Quarles & Brady LLP on

Shortly after publication of last week’s Client Alert on recent developments in artificial intelligence (AI) executive orders, the Trump Administration issued a new Executive Order with some additional clarification on the...more

Wiley Rein LLP

Trump Administration Issues New AI Executive Order

Wiley Rein LLP on

The Trump Administration has issued a new Executive Order (EO) on Artificial Intelligence (AI) that previews the new direction for federal AI policy. As we noted in a recent update, one of President Trump’s first actions in...more

Womble Bond Dickinson

USPTO Announces New Effort to Promote AI and Emerging Technologies

Womble Bond Dickinson on

The U.S. Patent and Trademark Office (USPTO) recently announced an official Artificial Intelligence Strategy that outlines how the Office plans to address the promise and challenges of artificial intelligence (AI) in its...more

Hogan Lovells

FDA’s evolving regulatory framework for AI use in drug & device clinical trials and research

Hogan Lovells on

U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, M.D., and other senior FDA officials recently published a “Special Communication” in JAMA describing FDA’s concerns with the use of AI in medical product...more

93 Results
 / 
View per page
Page: of 4

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide